NEW YORK (GenomeWeb) – Horizon Discovery today announced it has licensed technology from ERS Genomics related to the CRISRP-Cas9 gene editing system.

Under the terms of the non-exclusive agreement, Horizon can use the technology for research applications, such as the development and sale of research tools, kits, and reagents; performance of research services; development of genetically modified disease model cell lines; development and production of reference standard materials for molecular diagnostics; and internal target identification and validation research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.